tiprankstipranks
Eli Lilly And Company (LLY)
NYSE:LLY
US Market
LLY
Eli Lilly & Co
RESEARCH TOOLSreports
Want to see LLY full AI Analyst Report?

Eli Lilly & Co (LLY) Stock Forecast & Price Target

22,437 Followers
See the Price Targets and Ratings of:

LLY Analyst Ratings

Strong Buy
22Ratings
Strong Buy
20 Buy
2 Hold
0 Sell
Based on 22 analysts giving stock ratings to
Eli
Lilly & Co
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

LLY Stock 12 Month Forecast

Average Price Target

$1,290.79
▲(39.24% Upside)
Based on 22 Wall Street analysts offering 12 month price targets for Eli Lilly & Co in the last 3 months. The average price target is $1,290.79 with a high forecast of $1,500.00 and a low forecast of $1,135.00. The average price target represents a 39.24% change from the last price of $927.03.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"728":"$728","1501":"$1,501","921.25":"$921.3","1114.5":"$1,114.5","1307.75":"$1,307.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.50K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1290.7894736842104,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.29K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1135,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.14K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[728,921.25,1114.5,1307.75,1501],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1082.2,1114.3384615384616,1146.4769230769232,1178.6153846153848,1210.753846153846,1242.8923076923077,1275.0307692307692,1307.1692307692308,1339.3076923076924,1371.4461538461537,1403.5846153846155,1435.7230769230769,1467.8615384615384,{"y":1500,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1082.2,1098.2453441295547,1114.2906882591094,1130.336032388664,1146.3813765182185,1162.4267206477732,1178.472064777328,1194.5174089068826,1210.5627530364372,1226.608097165992,1242.6534412955466,1258.698785425101,1274.7441295546557,{"y":1290.7894736842104,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1082.2,1086.2615384615385,1090.323076923077,1094.3846153846155,1098.446153846154,1102.5076923076924,1106.569230769231,1110.6307692307691,1114.6923076923076,1118.753846153846,1122.8153846153846,1126.876923076923,1130.9384615384615,{"y":1135,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":741.871,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 76,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":770.449,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 74,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":756.975,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 79,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":729.031,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 70,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":821.422,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 73,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":858.68,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1054.312,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1071.045,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1040.599,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1016.22,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":952.879,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 76,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":961.674,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 90,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1082.2,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 84,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$1,500Average Price Target$1,291Lowest Price Target$1,135
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on LLY
David Risinger
Leerink Partners
Leerink Partners
$1,119→$1,232
Buy
32.90%
Upside
Reiterated
06/25/26
Eli Lilly price target raised to $1,232 from $1,119 at LeerinkEli Lilly price target raised to $1,232 from $1,119 at Leerink
Berenberg Bank Analyst forecast on LLY
Kerry Holford
Berenberg Bank
Berenberg Bank
$1,050→$1,135
Hold
22.43%
Upside
Reiterated
06/22/26
Eli Lilly price target raised to $1,135 from $1,050 at BerenbergEli Lilly price target raised to $1,135 from $1,050 at Berenberg
Barclays Analyst forecast on LLY
Emily Field
Barclays
Barclays
$1,400
Buy
51.02%
Upside
Reiterated
06/22/26
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT), Eli Lilly & Co (NYSE: LLY) and C4 Therapeutics (NASDAQ: CCCC)
Citi Analyst forecast on LLY
Geoff Meacham
Citi
Citi
$1,500
Buy
61.81%
Upside
Reiterated
06/16/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
BMO Capital Analyst forecast on LLY
Evan Seigerman
BMO Capital
BMO Capital
$1,300
Buy
40.23%
Upside
Reiterated
06/14/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jefferies Analyst forecast on LLY
Akash Tewari
Jefferies
Jefferies
$1,330→$1,350
Buy
45.63%
Upside
Reiterated
06/09/26
Eli Lilly price target raised to $1,350 from $1,330 at JefferiesEli Lilly price target raised to $1,350 from $1,330 at Jefferies
Bernstein Analyst forecast on LLY
Courtney Breen
Bernstein
Bernstein
$1,300
Buy
40.23%
Upside
Reiterated
06/09/26
Bernstein Sticks to Their Buy Rating for Eli Lilly & Co (LLY)
J.P. Morgan Analyst forecast on LLY
Chris Schott
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
06/09/26
Analyst Reaffirms Buy on Eli Lilly, Citing Durable Obesity Leadership and Multi‑Year Incretin Pipeline Upside
Truist Financial Analyst forecast on LLY
Srikripa Devarakonda
Truist Financial
Truist Financial
―
Buy
―
Reiterated
06/08/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Insulet (NASDAQ: PODD) and Novartis (NYSE: NVS)
Morgan Stanley Analyst forecast on LLY
Terence Flynn
Morgan Stanley
Morgan Stanley
$1,344
Buy
44.98%
Upside
Reiterated
06/08/26
Morgan Stanley Sticks to Its Buy Rating for Eli Lilly & Co (LLY)
Goldman Sachs Analyst forecast on LLY
Asad Haider
Goldman Sachs
Goldman Sachs
$1,260→$1,283
Buy
38.40%
Upside
Assigned
06/08/26
Buy Rating Reiterated on Eli Lilly as Obesity Pipeline Strength Justifies Unchanged $1,283 Price Target
Wells Fargo Analyst forecast on LLY
Mohit Bansal
Wells Fargo
Wells Fargo
$1,280
Buy
38.08%
Upside
Reiterated
05/27/26
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Corbus Pharmaceuticals (CRBP)
Bank of America Securities Analyst forecast on LLY
Jason Gerberry
Bank of America Securities
Bank of America Securities
$1,133→$1,251
Buy
34.95%
Upside
Reiterated
05/26/26
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Abivax SA Sponsored ADR (ABVX)
RBC Capital Analyst forecast on LLY
Trung Huynh
RBC Capital
RBC Capital
$1,250
Buy
34.84%
Upside
Reiterated
05/21/26
Eli Lilly's retatrutide Triumph-1 study a 'clean win', says RBC CapitalEli Lilly's retatrutide Triumph-1 study a 'clean win', says RBC Capital
Wolfe Research Analyst forecast on LLY
Alexandria Hammond
Wolfe Research
Wolfe Research
$1,325→$1,350
Buy
45.63%
Upside
Reiterated
05/21/26
Eli Lilly 'sets new bar' with retatrutide trial results, says Wolfe ResearchEli Lilly 'sets new bar' with retatrutide trial results, says Wolfe Research
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on LLY
David Risinger
Leerink Partners
Leerink Partners
$1,119→$1,232
Buy
32.90%
Upside
Reiterated
06/25/26
Eli Lilly price target raised to $1,232 from $1,119 at LeerinkEli Lilly price target raised to $1,232 from $1,119 at Leerink
Berenberg Bank Analyst forecast on LLY
Kerry Holford
Berenberg Bank
Berenberg Bank
$1,050→$1,135
Hold
22.43%
Upside
Reiterated
06/22/26
Eli Lilly price target raised to $1,135 from $1,050 at BerenbergEli Lilly price target raised to $1,135 from $1,050 at Berenberg
Barclays Analyst forecast on LLY
Emily Field
Barclays
Barclays
$1,400
Buy
51.02%
Upside
Reiterated
06/22/26
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT), Eli Lilly & Co (NYSE: LLY) and C4 Therapeutics (NASDAQ: CCCC)
Citi Analyst forecast on LLY
Geoff Meacham
Citi
Citi
$1,500
Buy
61.81%
Upside
Reiterated
06/16/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
BMO Capital Analyst forecast on LLY
Evan Seigerman
BMO Capital
BMO Capital
$1,300
Buy
40.23%
Upside
Reiterated
06/14/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jefferies Analyst forecast on LLY
Akash Tewari
Jefferies
Jefferies
$1,330→$1,350
Buy
45.63%
Upside
Reiterated
06/09/26
Eli Lilly price target raised to $1,350 from $1,330 at JefferiesEli Lilly price target raised to $1,350 from $1,330 at Jefferies
Bernstein Analyst forecast on LLY
Courtney Breen
Bernstein
Bernstein
$1,300
Buy
40.23%
Upside
Reiterated
06/09/26
Bernstein Sticks to Their Buy Rating for Eli Lilly & Co (LLY)
J.P. Morgan Analyst forecast on LLY
Chris Schott
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
06/09/26
Analyst Reaffirms Buy on Eli Lilly, Citing Durable Obesity Leadership and Multi‑Year Incretin Pipeline Upside
Truist Financial Analyst forecast on LLY
Srikripa Devarakonda
Truist Financial
Truist Financial
―
Buy
―
Reiterated
06/08/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Insulet (NASDAQ: PODD) and Novartis (NYSE: NVS)
Morgan Stanley Analyst forecast on LLY
Terence Flynn
Morgan Stanley
Morgan Stanley
$1,344
Buy
44.98%
Upside
Reiterated
06/08/26
Morgan Stanley Sticks to Its Buy Rating for Eli Lilly & Co (LLY)
Goldman Sachs Analyst forecast on LLY
Asad Haider
Goldman Sachs
Goldman Sachs
$1,260→$1,283
Buy
38.40%
Upside
Assigned
06/08/26
Buy Rating Reiterated on Eli Lilly as Obesity Pipeline Strength Justifies Unchanged $1,283 Price Target
Wells Fargo Analyst forecast on LLY
Mohit Bansal
Wells Fargo
Wells Fargo
$1,280
Buy
38.08%
Upside
Reiterated
05/27/26
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Corbus Pharmaceuticals (CRBP)
Bank of America Securities Analyst forecast on LLY
Jason Gerberry
Bank of America Securities
Bank of America Securities
$1,133→$1,251
Buy
34.95%
Upside
Reiterated
05/26/26
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Abivax SA Sponsored ADR (ABVX)
RBC Capital Analyst forecast on LLY
Trung Huynh
RBC Capital
RBC Capital
$1,250
Buy
34.84%
Upside
Reiterated
05/21/26
Eli Lilly's retatrutide Triumph-1 study a 'clean win', says RBC CapitalEli Lilly's retatrutide Triumph-1 study a 'clean win', says RBC Capital
Wolfe Research Analyst forecast on LLY
Alexandria Hammond
Wolfe Research
Wolfe Research
$1,325→$1,350
Buy
45.63%
Upside
Reiterated
05/21/26
Eli Lilly 'sets new bar' with retatrutide trial results, says Wolfe ResearchEli Lilly 'sets new bar' with retatrutide trial results, says Wolfe Research
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Eli Lilly & Co

3 Months
Louise ChenScotiabank
Success Rate
28/37 ratings generated profit
76%
Average Return
+8.92%
Copying Louise Chen's trades and holding each position for 3 Months would result in 75.68% of your transactions generating a profit, with an average return of +8.92% per trade.
1 Year
Geoff MeachamCiti
Success Rate
41/43 ratings generated profit
95%
Average Return
+42.05%
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 95.35% of your transactions generating a profit, with an average return of +42.05% per trade.
2 Years
Louise ChenScotiabank
Success Rate
37/37 ratings generated profit
100%
Average Return
+78.22%
Copying Louise Chen's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +78.22% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LLY Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
2
3
5
3
Buy
55
57
73
85
81
Hold
6
3
2
2
3
Sell
0
2
2
2
0
Strong Sell
0
0
0
0
0
total
61
64
80
94
87
In the current month, LLY has received 84 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. LLY average Analyst price target in the past 3 months is 1,290.79.
Each month's total comprises the sum of three months' worth of ratings.

LLY Financial Forecast

LLY Earnings Forecast

Next quarter’s earnings estimate for LLY is $8.80 with a range of $8.16 to $9.36. The previous quarter’s EPS was $8.55. LLY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year LLY has Performed in-line its overall industry.
Next quarter’s earnings estimate for LLY is $8.80 with a range of $8.16 to $9.36. The previous quarter’s EPS was $8.55. LLY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year LLY has Performed in-line its overall industry.

LLY Sales Forecast

Next quarter’s sales forecast for LLY is $20.48B with a range of $20.08B to $21.20B. The previous quarter’s sales results were $19.80B. LLY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year LLY has Performed in-line its overall industry.
Next quarter’s sales forecast for LLY is $20.48B with a range of $20.08B to $21.20B. The previous quarter’s sales results were $19.80B. LLY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year LLY has Performed in-line its overall industry.

LLY Stock Forecast FAQ

What is LLY’s average 12-month price target, according to analysts?
Based on analyst ratings, Eli Lilly And Company’s 12-month average price target is 1,290.79.
    What is LLY’s upside potential, based on the analysts’ average price target?
    Eli Lilly And Company has 39.24% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is LLY a Buy, Sell or Hold?
          Eli Lilly And Company has a consensus rating of Strong Buy which is based on 20 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Eli Lilly And Company’s price target?
            The average price target for Eli Lilly And Company is 1,290.79. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $1,500.00 ,the lowest forecast is $1,135.00. The average price target represents 39.24% Increase from the current price of $927.03.
              What do analysts say about Eli Lilly And Company?
              Eli Lilly And Company’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Streets Analysts.
                How can I buy shares of LLY?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.